research “Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
This review discusses the implications of renaming myelodysplastic syndromes as "myelodysplastic neoplasms" and argues that the "low-risk" label may misrepresent patient experiences and hinder research.